Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcomas

NCT03719430 is registered in ClinicalTrials.gov with Alexander Z. Wei, MD as lead sponsor.

NCT NCT03719430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03719430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcomas
Lead sponsor
Alexander Z. Wei, MD
Phase
Phase 2
Overall status
Completed
Start date
March 20, 2019
Completion date
December 11, 2025
Enrollment
27 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma